F. Vreeland

Clinical Pharmacodynamic Effects of the Growth Hormone Receptor Antagonist Pegvisomant: Implications for Cancer Therapy

L. Schaaf, Amarnath Sharma, D. Yin, 2007, Clinical Cancer Research.

A Phase I Dose-Escalation and Pharmacokinetic Study of Brostallicin (PNU-166196A), a Novel DNA Minor Groove Binder, in Adult Patients with Advanced Solid Tumors

J. Berlin, A. Lockhart, E. Fontana, 2004, Clinical Cancer Research.

A Phase I Dose-Escalation and Pharmacokinetic Study of Brostallicin (PNU-166196A), a Novel DNA Minor Groove Binder, in Adult Patients with Advanced Solid Tumors

J. Berlin, A. Lockhart, E. Fontana, 2004, Clinical Cancer Research.

Clinical use of aromatase inhibitors in the treatment of advanced breast cancer

A. Bhatnagar, H. Chaudri, P. Trunet, 1997, The Journal of Steroid Biochemistry and Molecular Biology.

Phase I trial of Taxotere: five-day schedule.

D. Moore, R. Pazdur, R. Newman, 1992, Journal of the National Cancer Institute.

Clinical experience with sorbinil--an aldose reductase inhibitor.

J. Collier, M. Peterson, G. Shaw, 1986, Metabolism: clinical and experimental.

Absolute bioavailability of letrozole in healthy postmenopausal women

J. Cardot, A. Sioufi, J. Godbillon, 1997, Biopharmaceutics & drug disposition.

Dose Ranging Evaluation of the Antiemetic Efficacy and Toxicity of Intramuscular Levonantradol in Cancer Subjects with Chemotherapy‐Induced Emesis

J. Stambaugh, J. McAdams, F. Vreeland, 1984, Journal of clinical pharmacology.

The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth

Adrian V. Lee, R. Schiff, C. Osborne, 2006, Breast Cancer Research and Treatment.